The reason why bone marrow cells home into the bone after intravenous administration is because a continuous production of Stromal Derived Factor-1 (SDF-1) by the bone marrow stromal compartments. The gradient of SDF-1 is also retains the early CD34+ bone marrow hematopoietic stem cells in the bone marrow. The current patent covers...
It is known that Sphingosine-1-phosphate mediates migration of mesenchymal stem cells. However, there are numerous receptors by which the effects of sphingosine-1-phosphate are mediated. While the sphingosine-1-phosphate receptor 1 is associated with migration, other activation of other receptors (such as sphingosine-1-phosphate...
Subsequent to myocardial infarction, cells of the injured myocardium release a variety of cytokines and mediators that are involved in mobilizing endogenous bone marrow stem cells and inducing their migration to the area of myocardial injury. One cytokine released is G-CSF, which in addition to possessing hematopoietic functions also is a great mobilizer of stem cells. In the current...
On of the interesting methods of manipulating stem cells is to increase their ability to “go where they are suppose to”. For example, it is known that when bone marrow or cord blood hematopoietic stem cells are injected intravenously into an irradiated recipient, the cells selectively home to the bone marrow and if enough cells migrate appropriately, hematopoietic reconstitution...
This patent is useful for stem cell mobilization, stem cell homing, as well as a variety of other applications involving various chemokines. Specifically, the invention covers peptides that antagonize or agonize receptors for IL-8, IP-10, MIP-1 alpha., MCP-1, RANTES, I-309, and CCL28. Inventors: Merzouk, Ahmed (Richmond, CA); Wong, Donald (Vancouver, CA); Salari, Hassan (Delta, CA)
Although this patent describes modulation of stem cell migration in the specification, the claims are restricted to the regulation of placental size. Specifically, the patent claims the use of IGF-2 to augment "placental growth, placental function, placental development and placental differentiation" in a mammal. The inventors appear to be the first to discover...
This patent covers the use of various carbohydrate presenting molecules for increasing amount of stem cell homing to tissue where stem cell migration is desired. Specific molecules that attract the stem cells which are covered include asialoorosomucoid and orosomucoid. This patent could be used to not only augment currented CD34 stem cell therapy efficacy but...
Hematopoietic stem cells stay in the bone marrow due in part to secretion of SDF-1 by bone marrow stromal cells. The chemotactic gradient of SDF-1 is also what causes hematopoietic stem cells to home to the bone marrow of the recipient after a bone marrow transplant. This invention covers some antagonists of the receptor for
This patent teaches the use of a naturopathic remedy for actually mobilizing stem cells into systemic circulation. The naturopathic remedy is blue green algae. This patent may be used for treating anything that benefits from mobilized stem cells ranging from stroke to myocardial infarction.
The area of stem cell mobilization is very exciting not only from the perspective of allowing for efficient harvest of peripheral blood stem cells, but also from the perspective of one day being able to mobilize endogenous stem cells to accelerate healing of various organs. In this patent a novel method of inducing mobilization of stem cells from the bone marrow, as well as inhibiting...